The global gene editing market is forecast to reach around $29 billion by 2032, with the goal of targeting underserved diseases, such as herpes simplex virus (HSV).
Researchers recently announced that they found an experimental gene therapy for genital and oral HSV that removed 90% or more of the infection.
They developed a potentially curative approach against HSV infection based on gene editing using HSV-specific meganucleases delivered by adeno-associated virus (AAV) vectors.
Read More
